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ABSTRACT
Objectives In rheumatoid arthritis (RA), treat-to-target
strategies require instruments for valid detection of joint
inﬂammation. Therefore, imaging modalities are
increasingly used in clinical practice. Optical spectral
transmission (OST) measurements are non-invasive and
fast and may therefore have beneﬁts over existing
imaging modalities. We tested whether OST could
measure disease activity validly in patients with RA.
Methods In 59 patients with RA and 10 patients with
arthralgia, OST, joint counts, Disease Activity Score (DAS)
28 and ultrasonography (US) were performed.
Additionally, MRI was performed in patients with
DAS28<2.6. We developed and validated within the
same cohort an algorithm for detection of joint
inﬂammation by OST with US as reference.
Results At the joint level, OST and US performed
similarly inproximal interphalangeal-joints (area under
the receiver-operating curve (AUC) of 0.79, p<0.0001)
andmetacarpophalangeal joints (AUC 0.78, p<0.0001).
Performance was less similar in wrists (AUC 0.62,
p=0.006). On the patient level, OST correlated
moderately with clinical examination (DAS28 r=0.42,
p=0.001), and US scores (r=0.64, p<0.0001).
Furthermore, in patients with subclinical and low disease
activity, there was a correlation between OST and MRI
synovitis score (RAMRIS (Rheumatoid Arthritis MRI
Scoring) synovitis), r=0.52, p=0.005.
Conclusions In this pilot study, OST performed
moderately in the detection of joint inﬂammation in patients
with RA. Further studies are needed to determine the
diagnostic performance in a new cohort of patients with RA.
INTRODUCTION
The prognosis of rheumatoid arthritis (RA) has
greatly improved with treatment targeting at remis-
sion.1 This requires instruments for valid detection
of disease activity. Generally, the 28-joint Disease
Activity Score (DAS28) is used for this. However,
DAS28 has not been validated for use in individual
patients, has considerable test–retest variability2 3
and is also inﬂuenced by several factors unrelated
to joint inﬂammation.4 5 Imaging techniques such
as ultrasonography (US) and MRI are more sensi-
tive for the detection of synovitis than physical
assessment,6 but they are not applied as standard
assessments yet.7 There is an unmet need for
objective, fast measurement of disease activity at
low cost, applicable during outpatient visits.
Optical spectral transmission (OST) measures the
transmission of light of speciﬁc wavelengths quanti-
tatively. The same technique is used in pulse oxim-
etry.8 In the presence of synovitis, the transmission
of light decreases,9 10 which is due to vascular
changes.11 There is one commercially available
optical device which measures reﬂection of light on
illumination, before and after intravenously admini-
strated indocyanine green (ﬂuorescence optical
imaging (FOI)).12 13 OST measures the transmis-
sion of light before and after temporarily impeding
the venous return of blood from the forearms.
Using this approach, OST through a single joint
(proximal interphalangeal (PIP)) has shown to cor-
relate with the detection of synovitis by physical
examination.14 A multijoint OST device (Full Hand
Prototype (FHP)) has been developed, which was
used in our current study. In this pilot study, we
tested whether the FHP could measure disease
activity accurately in patients with RA.
METHODS
Subjects
Fifty-nine patients with RA and 10 controls with
non-inﬂammatory arthralgia of unknown cause were
recruited at the outpatient clinics of the departments
of rheumatology at the University Medical Center
Utrecht (UMCU) and Regional Rheumatology
Center Eindhoven between November 2011 and
June 2012. The aim was to include 20 patients for
each category of disease activity, DAS28<2.6,
2.6≤DAS28≥5.1, DAS28>5.1. Preliminary stratiﬁca-
tion during recruitment was based on the DAS28 at
the time of the screening visit at the outpatient clinic.
Final stratiﬁcation was based on the DAS28 measured
at the day of examination, which resulted in 20
patients with DAS28<2.6, 26 with 2.6≤DAS28≥5.1
and 13 with DAS28>5.1. Time between recruitment
and enrolment was less than 3 weeks. In all subjects
clinical assessments, US and OSTwere performed. In
order to be clinically useful, an imaging technique
should be able to measure subclinical disease activity.
To examine this in more detail, we performed in
patients with DAS28<2.6 at recruitment, not only
US but also MRI. Exclusion criteria were age less
than 18 or over 90 years, signiﬁcant deformities of
the hand, wheelchair dependency, surgery of the
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wrist or hand in the preceding 3 months, light hypersensitivity,
pregnancy and/or breastfeeding. In the MRI subgroup only,
additional exclusion criteria were applied: allergy to gadolinium,
presence of MRI-incompatible metal objects in any part of the
body, renal insufﬁciency (deﬁned as Modiﬁcation of Diet in Renal
Disease (MDRD) <30 mL/min/1.73 m2) and/or claustrophobia.
All measurements were performed within a window of 4 h at the
University Medical Center Utrecht. The study complied with the
Declaration of Helsinki. The study protocol was approved by the
ethics committees of the UMCU and Maxima Medical Center
Eindhoven. All study participants gave written informed consent
prior to study inclusion.
Clinical assessment
Comorbidities, current drug use, presence of Raynaud’s phe-
nomenon and the presence of visible wounds on hands or
wrists were recorded. Subjects ﬁlled out a global assessment of
disease activity on a Visual Analogue Scale (0–100). A swollen
and tender joint count was performed by a physician (KLT)
and a research nurse (AJLM) in all subjects, in random order.
Table 1 Patient demographics and clinical data
Arthralgia
Rheumatoid arthritis
DAS28<2.6 2.6≥DAS28≤5.1 DAS28>5.1
Patients (number) 10 20 26 13
Age (year) 39±8 48±15 59±8 57±12
Female (%) 100 70 58 54
Duration of arthralgia (year) 3 (1–15) – – –
Duration of RA (year) – 3 (2–4) 9 (3–17) 1 (0–6)
ACPA positivity (%) 0 65 77 69
DAS28 3.2±0.9 1.7±0.4 3.8±0.8 5.9±0.6
ESR (mm 1st hour) 9 (5–13) 6 (3–10) 14 (8–24) 37 (21–55)
Raynaud’s phenomenon (%) 0 0 11 15
Use of β-blockers (%) 0 5 23 0
Use of calcium channel blockers (%) 0 15 0 0
Numbers are presented as mean±SD or median (IQR) unless mentioned otherwise.
Mean of the two physical examiners. Examined joints: shoulders, elbows, wrists, MCP and (P)IP joints of hands and knees.
ACPA, anti-citrullinated protein antibody; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; MCP, metacarpophalangeal; RA, rheumatoid arthritis.
Table 2 Involvement of wrists, MCP and PIP joints
Arthralgia
Rheumatoid arthritis
DAS28<2.6 2.6≥DAS28≤5.1 DAS28>5.1
No. of affected joints
Tender joints (0–22)* 1 (0–4) 0 (0–1) 2 (1–6) 11 (5–13)
Swollen joints (0–22)* 0 (0–0) 0 (0–1) 2 (1–4) 6 (4–9)
GSUS>1 (0–22) 0 (0–0) 0 (0–0) 1 (0–2) 2 (1–5)
PDUS>0 (0–22) 0 (0–0) 0 (0–1) 1 (0–4) 2 (1–6)
US synovitis (GSUS>1 and/or PDUS>0) (0–22) 0 (0–0) 0 (0–1) 1 (0–4) 2 (1–6)
GSUS tenosynovitis (0–22) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–1)
PDUS tenosynovitis (0–22) 0 (0–0) 0 (0–1) 0 (0–2) 1 (0–5)
US inflammation (GSUS>1 and/or PDUS>0 and/or PDUS tenosynovitis) (0–22) 0 (0–0) 1 (0–2) 2 (0–5) 3 (2–7)
MRI joint count (synovitis>0) (0–6)† – 5 (3–5) 4 (4–5) –
MRI joint count (bone marrow oedema) (0–6)† – 1 (0–1) 1 (0–1) –
Severity of affected joints
GSUS joint index (synovitis+tenosynovitis) (0–88) 1 (0–1) 2 (1–3) 5 (2–7) 9 (2–13)
PDUS joint index (synovitis+tenosynovitis) (0–88) 0 (0–0) 0 (0–2) 2 (0–7) 5 (2–12)
US joint index (GSUS synovitis+GSUS tenosynovitis+PDUS synovitis+PDUS
tenosynovitis) (0–176)
1 (0–1) 2 (1–4) 6 (3–1) 13 (4–27)
RAMRIS synovitis (0–21) – 6 (4–8) 6 (4–7) –
RAMRIS bone marrow oedema (0–69) – 1 (0–2) 1 (0–2) –
RAMRIS (0–320) – 13 (8–18) 19 (10–23) –
OST joint index‡ 4.13 (3.42–5.49) 4.40 (3.48–5.10) 5.90 (4.37–7.49) 7.35 (4.27–10.28)
Number of affected joints are presented as median (IQR).
*Average of the two physical examiners.
†MCP 1–5 and radiocarpal and intracarpal joints on right side only, MRI was performed in patients with DAS28<2.6 at recruitment; all patients with DAS28<2.6 at the study day and
additionally 7 patients with 2.6≥DAS28≤5.1 (median (IQR) DAS28 of these 7 patients was 3.2 (2.9–3.3)).
‡Kruskal–Wallis one-way analysis of variance p=0.001.
DAS, Disease Activity Score; GSUS, grey-scale US; MCP, metacarpophalangeal; OST, optical spectral transmission; PDUS, power Doppler US; PIP, proximal interphalangeal; RAMRIS,
Rheumatoid Arthritis MRI Scoring; US, ultrasonography.
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The examiners were blinded to the result of each other’s
assessments and other study measurements. The kappa for
inter-rater agreement for tender joints was 0.50 and for
swollen joints 0.52.
Ultrasonography
US was performed by one experienced examiner (DFTC (phys-
ician)) who was blinded to the results of other study measure-
ments. A MyLab 60 system (Esaote, Genua, Italy) with an
18-6 MHz linear array transducer was used. Grey-scale US
(GSUS) was performed of metacarpophalangeal (MCP) 1–5
(dorsal side), (P)IP 1–5 of hands (volar side), radiocarpal and
mid-carpal joints (dorsal side) and ﬂexor and extensor tendons
of ﬁngers and wrists. Patient and probe positioning were accord-
ing to EULAR guidelines.15 Synovitis on GSUS and power
Doppler US (PDUS) was classiﬁed using Outcome
Measurements in Rheumatology Clinical Trials (OMERACT)
deﬁnitions of ultrasonographic joint pathology and graded semi-
quantitatively according to a modiﬁcation of Szkudlarek’s
grading system,16 combining the criteria for joint effusion and
synovial thickening. PDUS was performed only if the GSUS
synovitis score was greater than 0. This study was designed well
before the introduction of the OMERACT scoring system for
tenosynovitis.17 At the time, no generally accepted criteria were
available and the range of reference values for hypoechoic or
anechoic rims around a tendon is very broad. Therefore, we
chose to deﬁne GSUS tenosynovitis as a hypoechoic or anechoic
rim around a tendon exceeding 2 mm.18 This was registered as
being absent or present. PDUS of tendons was performed in
case of (any) hypoechoic or anechoic thickened tissue with or
without ﬂuid within the tendon sheath seen in two perpendicu-
lar planes. This was registered as being absent or present.
Grade 1 GSUS synovitis has also been found in healthy sub-
jects18 19 and is of limited prognostic value in RA.19 20
Therefore, US inﬂammation was deﬁned as (GSUS synovitis >1
and/or PDUS synovitis >0 and/or GSUS/PDUS tenosynovitis
>0). For individual subjects, the number of joints with inﬂam-
mation was counted (US joint count). Also, the sum of GSUS
synovitis, GSUS tenosynovitis, PDUS synovitis and PDUS teno-
synovitis scores were calculated (US joint index).
MRI
Imaging was performed on a 1.5 Tesla MRI. (Philips Ingenia
1.5T, Philips Healthcare, Eindhoven, The Netherlands). The
following sequences were acquired: Coronal T1-weighted turbo
spin-echo images (TR/TE, 450/7.2; matrix size, 328×159; ﬁeld
of view, 18 cm; slice thickness, 2.5 mm), transversal
T1-weighted turbo spin-echo images (TR/TE, 500/12; matrix
size, 300×185; ﬁeld of view, 12 cm; slice thickness, 2.5 mm),
Coronal T2-weighted short-tau inversion recovery images (TR/
TE, 3251/150; inversion time, 150; matrix size, 328×140; ﬁeld
of view, 18 cm; slice thickness, 2.5 mm). T1 images were
acquired before and after intravenous gadolinium contrast
administration. Images were scored by one experienced MRI
reader and rheumatologist according to OMERACT Rheumatoid
Arthritis MRI Scoring (RAMRIS) method, evaluating synovitis in
MCP2-5 and the wrists. The reader was blinded to the results of
other study measurements. The same image set was scored twice
with at least a 2-week interval; results were averaged. The kappa
for intrarater agreement was 0.25; if joints with synovitis grade
1 were excluded, kappa was 0.80. Similar to US, the number of
joints with synovitis was counted (MRI joint count).
Optical transmission measurements
OST measurements were performed with the FHP in a standar-
dised way operated by a rheumatology nurse (AJLM). Both
hands were inserted through cylindrical openings that contained
pressure cuffs. light-emitting diode (LED) lights (wavelengths of
660 and 810 nm) illuminated the (P)IP, MCP and wrist joints of
both hands and reference areas from the palmar side. Light
transmitted through the joints and reference areas was recorded
continuously at the dorsal side by charge-coupled device (CCD)
camera with a frame rate of at least six per second, alternatingly
Figure 1 Subclinical inﬂammation in a patient with rheumatoid
arthritis in clinical remission. Representative images of a patient
without clinically detectable arthritis. All imaging techniques show
synovitis of both wrists and metacarpophalangeal (MCP)3 of the right
hand. Both hands with (A) Full Hand Proto, (B) grey-scale and power
Doppler ultrasonography of joints of left (a) and right wrist (b) and left
and right MCP3 (c and d) (C) MRI of right wrist T2 short-tau inversion
recovery (STIR) (a) and MCP joints of the right MCP (b, T1 with
gadolinium enhancement).
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for the 660 nm wavelength, the 810 nm wavelength and
without illumination (background image). A complete measure-
ment was performed within 90 s: ﬁrst, inﬂation of the cuff to
5 mm Hg (15 s); second, inﬂation of the cuff to 50 mm Hg
(60 s) and ﬁnally deﬂation of the cuff (15 s).
Image analysis was performed by PBLM using in-house devel-
oped software (InFlame RA-120159, December 10, 2012),
blinded to the results of other study measurements. Regions of
interest (ROI) were traced manually for all joints ( joint ROI)
and automatically for a position distal to each joint (reference
ROI) based on the pictures taken by the CCD camera.
Landmarks for joint ROI were broadening of the phalanx and
wrinkles of the skin for (P)IP-joints, web between the ﬁngers for
MCP joints and curvatures of distal radius and ulna. An ROI
consisted of approximately 100 pixels. The recorded intensity
of each pixel in a ROI versus the measurement time was ﬁtted
to a curve representing the response to inﬂation and deﬂation of
the pressure cuff, separately for the 660 nm and the 810 nm
Figure 2 Patient level: relationship between optical spectral transmission (OST) and clinical examination, ultrasonography (US) and MRI. (A)
Correlation between OST and clinical examination (DAS28, swollen joint count of 28 joints and tender joint count of 28 joints). (B) Correlation
between OST and US, upper three panels with count of number of joints with grey-scale US (GSUS) synovitis (left panel), count of number of joints
with power Doppler US (PDUS) synovitis (middle panel) and count of joints with inﬂammation with US (right panel). US inﬂammation was deﬁned
as (GSUS synovitis >1 or PDUS synovitis >0 and/or GSUS/PDUS tenosynovitis >0). Lower three panels show correlation of OST with joint indexes
(sum of semi-quantitative US scores) of GSUS synovitis (left panel), PDUS synovitis (middle panel) and US inﬂammation (right panel). (C) Correlation
between OST and MRI. Rheumatoid Arthritis MRI Scoring (RAMRIS) (left panel) and its components (RAMRIS synovitis (middle panel) and RAMRIS
bone marrow oedema (right panel)).
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wavelength (the optical transmission response curve, see online
supplementary ﬁgure S1). The optical response curve of a pixel
could be described by eight curve parameters per wavelength,
that is, 16 curve parameters for both wavelengths combined.
The average of a curve parameter over pixels in an ROI was cal-
culated, giving 16 parameters per ROI. Reference ROIs allowed
for correction for systemic effects unrelated to inﬂammation,
such as body temperature and the use of vasoactive medication.
This was done by subtracting reference ROI parameters from
joint ROI parameters and then dividing this difference by the
average of reference ROI parameters and joint ROI parameters.
Thus, image analysis yielded 16 normalised parameters per joint
for use in regression analyses.
Statistical analysis
We developed and internally validated an algorithm for detec-
tion of joint inﬂammation by OSTwith US as reference by mul-
tiple regression analysis. Data of all patients were used in the
development and internal validation. The dependent variable
was deﬁned as the maximum of GSUS and PDUS scores for
synovitis and tenosynovitis (range 0–3), and the normalised
joint parameters as independent variables. A stepwise forward
selection procedure with adjusted R2 testing was used to deter-
mine which variable to add. This was repeated until either R2
no longer increased (cut-off value of 0) or, to prevent overﬁtting
of the model, a maximum of four parameters had been selected.
This was done separately for each joint region, so separately for
(P)IP, MCP and wrists. We tested whether individual observa-
tions exerting undue inﬂuence on the coefﬁcients in the regres-
sion analysis (outliers) were present and if so they were removed
from the development phase. The regression analysis with the
four parameters as independent variables per joint region was
then performed using leave-one-out cross validation to detect
and prevent overﬁtting. In this analysis, the model is repeatedly
reﬁt, leaving out at each ﬁt a different, single patient. The
regression coefﬁcients thus obtained are used to calculate OST
values for the left-out observation. For individual subjects, an
OST joint index over all joints ((P)IP 1–5, MCP 1–5 and wrists
of both hands) was calculated. The diagnostic performance of
OST was compared with clinical examination, DAS28, US and
MRI by receiver operating curve analyses with 95% CI estima-
tion, separately at the patient level (one score per patient) and
individual joint level (one score per joint). Presence (yes/no) of
(teno)synovitis on US was used as reference. Correlations were
calculated using Spearman’s rank correlation coefﬁcient.
Differences between group medians were tested for signiﬁcance
using either the Mann–Whitney U test for two groups or the
Kruskal–Wallis one-way analysis of variance for three or more
groups. p Values below 0.05 (two-sided tests) were considered
to be statistically signiﬁcant. Inter- and intrarater agreement was
calculated by the kappa statistic. The multiple regression ana-
lyses were performed using Hemics in-house software (InFlame
RA-120159), all other analyses by SPSS version 21.
RESULTS
Subjects
Demographic and clinical data are reported in table 1. Table 2
depicts the number and severity of affected PIP, MCP and wrist
joints per patient with clinical examinations, US and OST.
Optical transmission
All subjects tolerated the OST measurements well; no adverse
events or side effects were observed. Figure 1 depicts an
example of the results of OST, US and MRI in a patient in
Figure 2 (Continued).
Figure 3 Area under the curve (AUC) between optical spectral
transmission (OST) and ultrasonography (US) at the joint level. Area
under ROC of the OST in all joints (AUC 0.81, 0.77 to 0.84, p<0.0001),
(P)IP joints (AUC 0.79, 0.72 to 0.86, p<0.0001), metacarpophalangeal
(MCP) joints (AUC 0.78, 0.71 to 0.83, p<0.0001) and wrists (0.62, 0.52
to 0.72, p=0.018) (US as reference).
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clinical and DAS28 remission. One patient was identiﬁed as an
outlier. We looked into reasons for this, such as presence of
Raynaud’s phenomenon or use of vasoactive drugs. We could
not identify an explanation. This patient was therefore left out
of the analyses for the development of the algorithm, but not of
the validation. This was a patient with many active joints. The
OST scores of the subjects with Raynaud’s phenomenon and/or
using drugs that may alter peripheral blood ﬂow were not
outliers.
Comparison of OST with clinical examination, US and MRI
Median OSTwas different between the four groups (p=0.001).
The correlation coefﬁcients between OST and US were higher
than those between OST and clinical examination (ﬁgure 2).
The correlation coefﬁcients between OST and MRI and OST
and clinical examination were about similar; however, they are
difﬁcult to compare since MRI was only performed in patients
with remission or low disease activity and restricted to wrist and
MCP joints of one hand.
Joint level: comparison of OST scores with those at US
Diagnostic performance of OSTwas tested with inﬂammation as
detected by US as reference standard (ﬁgure 3). Overall, OST
had a good performance (AUC 0.81, 95% CI 0.77 to 0.84).
When testing separately for the (P)IP, MCP and wrists joints, the
OST of the (P)IP and MCP joints showed a good discrimination
(AUC of 0.79, 95% CI 0.72 to 0.86, p<0.0001 and 0.78, 95%
CI 0.71 to 0.83, p<0.0001, respectively). For the wrists it was
poor (AUC 0.62, 95% CI 0.52 to 0.74, p=0.006). Since OST
generates quantitative results, values for sensitivity and speciﬁ-
city of OST depend on the chosen cut-off value (ﬁgure 3). The
values for inﬂammation as deﬁned by OSTwith maximum sensi-
tivity and speciﬁcity were 0.11 for the (P)IP joints (sensitivity of
83%, speciﬁcity of 64%), 0.26 for the MCP joints (sensitivity
of 70%, speciﬁcity of 74%) and 1.0 for the wrists (sensitivity of
39%, speciﬁcity of 87%). In comparison, the test characteristics
of clinical examination (of the two examiners combined) of
swollen joints were sensitivity 59%, speciﬁcity 86% for the PIP
joints, a sensitivity 42% and a speciﬁcity of 93% for the MCP
joints and a sensitivity 37% and speciﬁcity of 89% for the wrists
(ﬁgure 4).
DISCUSSION
In this study, we found that OST measurements agreed moder-
ately with clinical assessments, US and MRI. The level of agree-
ment was highest with items (directly) reﬂecting synovial
vascularity, such as PDUS. As light does not penetrate through
bone, we found no agreement between OST and MRI bone
marrow oedema. Diagnostic performance of OST was better in
small hand joints (MCP and (P)IP joints) than in the wrists. The
sensitivity (but not speciﬁcity) of detection of synovitis was
higher than that of clinical examination for (P)IP (83% vs 59%)
and MCP joints (70% vs 42%); it was similar for the wrists
(39% vs 37%). The sensitivity and speciﬁcity are, however,
lower than those for US and MRI,6 but regular use of these
techniques is not feasible in most clinics. Our pilot study shows
an increased detection rate which may be clinically relevant,
provided that the results are replicated in new cohorts.
Studies on FOI, an invasive technique using light to detect
inﬂammation, have been published earlier.12 13 21–23 It seems
that in FOI as well as in OST, the diagnostic performance is
inversely related to the size of the joint. The differences in
design (such as investigated joints areas, diagnosis) and tech-
nique used in the FOI studies hamper the full comparison of
these results with our own. However, our study shows at least
equivalent, or even slightly higher, sensitivity and speciﬁcity at
detecting synovitis at the joint level, than the commercially
available device for FOI. Additional advantages of our technique
are its non-invasiveness and the generation of quantitative
results ruling out interobserver variability.
This study has some limitations. There was a risk of model
overﬁtting because US was used both as reference standard in
Figure 4 Example of diagnostic
performance of optical spectral
transmission (OST) versus
ultrasonography (US) and clinical
examination at a chosen cut-off. Since
OST generates quantitative results,
values for sensitivity and speciﬁcity of
OST depend on the chosen cut-off
value. The values for inﬂammation as
deﬁned by OST with maximum
sensitivity and speciﬁcity were 0.26 for
the metacarpophalangeal (MCP) joints
(sensitivity of 70%, speciﬁcity of 74%),
0.11 for the proximal interphalangeal
((P)IP) joints (sensitivity of 83%,
speciﬁcity of 64%) and 1.0 for the
wrists (sensitivity of 39%, speciﬁcity of
87%). This ﬁgure shows the number of
correctly classiﬁed joints with and
without inﬂammation (US as reference)
by OST (using the above-mentioned
cut-off values) as the overlapping parts
of the red and the blue circles per joint
type. Similarly, the number of correctly
classiﬁed joints by clinical examination
(swollen joints) are shown as the
overlapping parts of the blue and the
green circles. Numbers denote the
number of patients in a category.
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the development of the algorithm and in the evaluation of diag-
nostic performance. We have tried to reduce overﬁtting by using
a relatively large development sample and leave-one-out cross
validation. We think this strategy was successful because we also
found a correlation between OST and MRI synovitis and MRI
was not used in development of the algorithm. However, valid-
ation in a new cohort is still mandatory, especially since rela-
tively few patients with severe synovitis were present in our
study.24 25 Another possible limitation is that we used subjects
with arthralgia as controls. In clinical practice, one wants to dif-
ferentiate between arthritis and arthralgia. However, it is well
known that in a subgroup of subjects, arthralgia may evolve in
inﬂammatory arthritis and subclinical inﬂammation may already
be present.26 None of the subjects in our study developed
inﬂammatory arthritis (>1 year after study completion). The
diagnostic performance of OST in the wrists was rather poor,
which may be related to the limited tissue penetration of light
through larger structures. In addition, there was a low number
of subjects with GSUS tenosynovitis. This may have been related
to the rather strict deﬁnition. Low-grade PDUS negative teno-
synovitis may have been missed. Further, US and OSTwere per-
formed each by a single examiner (DFTC and AJLM,
respectively). Therefore, interobserver variability could not be
calculated. Intraobserver agreement for MRI was low; the agree-
ment was good if joints with low-grade synovitis (grade 1) were
excluded. Further, it has been shown that the interobserver reli-
ability of US of the wrists is only moderate,27 28 which may be
related to the (more) complex anatomy of the wrist in compari-
son with PIP and MCP joints. It is subject of further studies
whether technical adjustments leading to more light penetration
through the wrists are able to improve the accuracy of OST
measurements of the wrists. Also, in the adjusted FHP, image
analysis will be automated; OST will then be an operator-
independent technique. Finally, and similar to other imaging
techniques, before OST can be used to monitor patients with
RA, its sensitivity to change should be investigated. New studies
to evaluate diagnostic performance and sensitivity to change in
a new cohort of patients with RA are planned.
In conclusion, OST is a new imaging technique that generates
fast and quantitative results. In this pilot study, OST performed
moderately in the detection of joint inﬂammation in patients
with RA. Further studies are needed to determine the diagnostic
performance in a new cohort of patients with RA.
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